$300.00
0.00%
Nasdaq, Fri, Sep 06 2024
ISIN
US34986J1051
Symbol
FWP
Sector
Industry

Forward Pharma A/S Sponsored ADR Stock price

$300.00
+0.00 0.00% 1M
+0.00 0.00% 6M
-100.00 25.00% YTD
+298.00 14,900.00% 1Y
-1,957.14 86.71% 3Y
-1,423.60 82.59% 5Y
-6,041.87 95.27% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.00 0.00%
ISIN
US34986J1051
Symbol
FWP
Sector
Industry

Key metrics

Market capitalization $7.45m
Short interest 4.71%

Is Forward Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Forward Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Forward Pharma A/S Sponsored ADR:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Forward Pharma A/S Sponsored ADR:

Hold
100%

Financial data from Forward Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '21
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.64 3.64
18% 18%
-
- Research and Development Expense 0.23 0.23
30% 30%
-
-3.87 -3.87
13% 13%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.87 -3.87
13% 13%
-
Net Profit -1.89 -1.89
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forward Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forward Pharma A/S Sponsored ADR Stock News

Neutral
GlobeNewsWire
more than one year ago
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. ...
Neutral
GlobeNewsWire
almost 2 years ago
COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward's petition for review (the “Petition”) of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by t...

Company Profile

Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Claus Svendsen
Employees 4
Founded 2005
Website www.forward-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today